You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature

Article info

Article menu
Review
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature

Authors

  • Lisa L Liu Department of Oncology-Pathology, Karolinska Institute, Stockholm, SwedenTheme Cancer, Karolinska University Hospital, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Marcus Skribek Department of Oncology-Pathology, Karolinska Institute, Stockholm, SwedenTheme Cancer, Karolinska University Hospital, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Ulrika Harmenberg Department of Oncology-Pathology, Karolinska Institute, Stockholm, SwedenTheme Cancer, Karolinska University Hospital, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Marco Gerling Theme Cancer, Karolinska University Hospital, Stockholm, SwedenDepartment of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden PubMed articlesGoogle scholar articles

Citation

Liu LL, Skribek M, Harmenberg U, et al
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature
Journal for ImmunoTherapy of Cancer 2023;11:e005841. doi: 10.1136/jitc-2022-005841
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.